Wednesday, March 3, 2010

Topic Discussion: OUCH!! Should Anesthesia Hurt??

“It will burn for a few seconds, then become numb…” Sound familiar? That’s how I describe the local infiltration of lidocaine to patients. In order to decrease the pain associated with the administration of lidocaine, our interventional radiology department has taught nephrologists to use lidocaine buffered with sodium bicarbonate (1 part NaHCO3 for 9 parts lidocaine) during local anesthesia in preparation for ultrasound guided kidney biopsies. A quick literature search reveals much support for this technique. One hypothesis is that the buffered solution has less protonated molecules which are lipophilic and can more readily enter the myelin sheath resulting in a more rapid onset of action. A second idea is that the buffered solution has less associated discomfort simply because it has a more physiologic pH.

On the other hand, one study showed that the administration rate of lidocaine may have more influence on the perceived pain associated with injection than does buffering. Slow, unbuffered injections were associated with less perceived pain than rapid, buffered injections. (http://www.annemergmed.com/article/S0196-0644(98)70278-1/abstract)

Tuesday, March 2, 2010

TOPIC DISCUSSION: Alcohol Poisonings, gaps and osmoles

This weeks Kidney International's Whats your diagnosis section discusses a case of Diethylene glycol poisoning. ( image courtesy on left: Precious Body Fluids Blog)
Of all the alcohol poisonings, its important to distinguish which one you are dealing with. The article has a nice table that shows the similarities and differences of them.
Methanol poisoning usually has acute renal failure, met acidosis ( part of MUDPILES), and increased or normal osmolar gap; there is some neurological and visual disturbances.
Propylene glycol is usually seen with ativan drips, is seen with acute renal failure, metabolic acidosis and sometimes an osmolar gap but other findings are negative.
Ethylene glycol, another cause of metabolic acidosis and increased osmolar gap, you see with renal failure and + calcium oxalate crystals.
The Diethylene glycol poisoning is more rare but can happen as in this case. Its usually seen with acute renal failure, + metabolic acidosis and sometimes an osmolar gap but very frequently as noted in this article with neurological facial nerve pals and mild hepatitis.
Isopropyl alcohol is a classic one that has an elevated osmolar gap but no anion gap.
There is always something hiding in the gap. Even a low osmolar gap is abnormal.
take a look at this table I saw in Canadian medical association journal. I think that this table is a nice review.
Says it all.

Belatacept approved by FDA

What is Belatacept and is it going to change the face of transplantation? Its a fusion protein composed of components of  TLA-4, extracellular domain of IgG1.  The drug can selectively block the T cell activation by inhibiting this costimulatory molecule CTLA-4.   From the researchers mainly at UCSF, a landmark paper was published few years ago in NEJM.
They assigned renal tranplant patients to receive an intensive or less intensive of belatacept or cyclosporine. All patients were induced with the same agent of basiliximab. All received steroids and MMF.  At six months, they evaluated that the incidence of acute rejection was no different in two groups. CAN, and decrease in GFR was less common in the belatacept arm.

This drug might show promise. Lets see once more widespread use of it is noted. It might allow us to spare cyclosporine or tacrolimus use in many of our patients. This is important as one of the most common causes of graft loss these days is not rejection but chronic calcineurin toxicity or chronic changes due to medications. The effect on the pancreas by these drugs is also not benign and the most common glomerular disease post transplant still remains to be diabetes.
Lets await and see.

Protocol Biopsies in Renal Allograft Recipients

Please see the link from an excellent website tool: Nephrology on Demand.
I encourage all to use it. It has latest information and classic nephrology articles for everyones use.
Very easy to use and easy access.


Protocol Biopsies in Renal Allograft Recipients

Sunday, February 28, 2010

CLINICAL CASE 5


After several weeks of ACEI or ARB use, the plasma aldosterone levels return to pretreatment levels in 40% of patient. What is this phenomenon called?

Aldosterone Escape 66%
Aldosterone Breakthrough 22%
Aldosterone Resistance 0%
Aldosterone Return 11%


Most of you all said Aldosterone escape and that is incorrect. The correct answer is Aldosterone Breakthrough. There is no such thing as aldosterone resistance or return.
A recent editorial in Nature Nephrology from Feb 2010 issue talks about the difference in these two phenomenon( escape vs Breakthrough).  
Aldosterone escape (AE) is as follows: when you have too much aldesterone in your body, there is an initial decrease in urinary sodium excretion, and renal sodium retention is increased.  However, urinary sodium excretion subsequently increases to balance the sodium intake before detectable edema develops. This phenomenon is called AE and is the reason why edema formation is not a characteristic of primary hyperaldo state.  Multiple mechanisms as described in the above linked editorial are responsible for the AE and prevention of edema.
What is Aldosterone Breaktrough( AB): When we uses ACEI and ARBS medication to inhibit the RAAS system, large increase in renin occurs in administration of these medications. People who treat hypertension with a renin or non renin mediated methods are familiar to this concept that renin will increase with ACEI and ARBs initiation, when you check the level in the plasma, its high.  Interestingly after several weeks of using these medication,
the aldosterone level returns to pre treatment levels in 30-40% of patients. This phenomenon is called AB.  Patients who develop this might have worse outcomes and eventually start not responding to ACEI and ARBS.  This editorial suggests that perhaps direct renin inhibitors or Vitamin D might decrease that renin drive and exert a better profile. 
I think we need to know about this novel concept often confused with the escape.
Please look at the following references as well

Bomback et al. Nature Clinical Pract Nephrol 3, 486-492 ;2007
Doorenbos et al. Nature Clinical Pract Nephrol 5, 691-700;2009

We can't really escape from this new breakthrough.

Friday, February 26, 2010

Luminex Technology



We discussed a review article during our transplant clinic morning session about Luminex technology for HLA antibody detection in organ transplantation published in Nephrology 2009; and would like to share it with you.

Pre-formed donor-specific human leukocyte antigen (HLA) class 1 antibodies (DSA) in renal transplant recipients causes hyperacute rejection; there has been an imperative to test all potential recipients prospectively for HLA antibodies to avoid transplanting incompatible grafts.

Since was first developed until recently, the method universally used for antibody detection was the complement-dependent cytotoxicity (CDC) assay. In recent years, solid phase assays have been introduced as methods for HLA antibody screening which have again redefined the definition of pre-sensitization. Luminex is a solid phase assay which consists of a series of polystyrene microspheres (beads), containing fluorochromes. Test is run as shown in the Figure.

Another important concept is PRA (Percent Reactive Antibody); it is the percentage of cells in a random panel which contains all known HLA types; giving positive results with anti-serum. PRA is useful in estimating the probability of a patient receiving a crossmatch-negative kidney.

By referring to this review study, the comparison and advantages of Luminex over CDC:
1-CDC checks for cell death caused by complement fixing antibodies against any cell antigen, while DSA by Luminex checks for the presence of the antibody against HLA type ONLY.
2-Luminex DSA is much more sensitive and can detect Donor-Specific HLA antibodies which in some cases associated with rejection in the presence of negative donor CDC cross-match. Large studies by Gibney et al and Smith et al indicated that a further subset of patients with DSA detectable only by Luminex is at high risk of graft rejection
3-CDC method can detect any Ab directed at the cell surface of a B or T cells; HLA and non-HLA antibodies and these antibodies are complement dependent in causing cell death. Luminex on the other hand detects ONLY the HLA antibodies itself, it doesn’t discriminate between complement fixing or non-compliment fixing HLA-Ab.

The question is: whether those non-compliment fixing Ab are detrimental to the graft and, if not, are we excluding patients from receiving compatible graft by using Luminex tech.
As per Washerman et al C4d+ “complement fixing Ab”, Flow + “Luminex positive” HLA class 1 antibodies graft survival is inferior to C4d -, flow + and flow – patients.

Now, what about those non-compliment fixing antibodies that are detected by Luminex, do they have an effect on the graft?
Smith et al showed that 1 year survival of renal graft of patients with C4d+ DSA was 20%, C4d – DSA was 54%, C4d + non-DSA patients was 91%. The interesting observations are the profound negative effect of the compliment fixing antibody on graft survival and also the reduction in graft survival of the C4d- DSA+

Other significant benefit of Luminex is detecting HLA-class 2 Ab in pre- and post-transplant with high level of sensitivity.

Having the fact that Luminex is far more sensitive than CDC, and at least in many cases detects additional clinically relevant Ab, the question is Can Luminex HLA replace CDC?
Also, keep in mind that on the other hand some patients with CDC-neg and Luminex positive DSA had uneventful post transplant course without evidence of rejection! So, having too much sensitive test can potentially contribute to denying some patients a suitable Graft?!

Thursday, February 25, 2010

IN THE NEWS ---> CLASSIFICATION FOR DIABETIC NEPHROPATHY

Recent issue of JASN talks about this interesting topic.
Alas, more classifications to add to our terminology.  This one might be useful. The Renal Pathology Society made a system for DM Nephropathy now.  They divided  diabetic nephropathy into four hierarchical glomerular lesions with a separate evaluation for degrees of interstitial and vascular involvement. Biopsies diagnosed as diabetic nephropathy were classified as follows: 
Class I, glomerular basement membrane thickening: isolated glomerular basement membrane thickening.
Class II, mesangial expansion, mild (IIa) or severe (IIb): glomeruli classified as mild or severe mesangial expansion but without nodular sclerosis (Kimmelstiel-Wilson lesions) or global glomerulosclerosis in more than 50% of glomeruli. 
Class III, nodular sclerosis (Kimmelstiel-Wilson lesions): at least one glomerulus with nodular increase in mesangial matrix (Kimmelstiel-Wilson) without changes described in class IV. 
Class IV, advanced diabetic glomerulosclerosis: more than 50% global glomerulosclerosis with other clinical or pathologic evidence that sclerosis is attributable to diabetic nephropathy.

How useful is this going to be clinically? How many diabetic patients do we biopsy nowadays? This might be useful for prognosticating if we had a biopsy specimen in a patient

All Posts

Search This Blog